Therapy Areas: Cardiovascular
Ofev Slows Progression of IPF Beyond Four Years, Study Finds
17 September 2018 - - Results from INPULSIS-ON, published in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev (nintedanib) in patien...
AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
17 September 2018 - AstraZeneca Plc (LON:AZ), a global, science-led biopharmaceutical company, and MedImmune, the company's global biologics research and development arm, announced on Friday the ...
BioCardia wins two new US patents to develop cardiac cell therapies
17 September 2018 - Cardiovascular regenerative therapy company BioCardia Inc (OTC:BCDA) reported on Friday the receipt of two patents in the US covering the methods of preparing mesenchymal stem cell...
Endpoint Data from Alnylam's APOLLO Phase 3 Study of Patisiran Published
14 September 2018 - - Data from exploratory cardiac assessments in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediat...
Dr. Reddy's Laboratories Launches Generic Version of Bloxiverz in the US Market
13 September 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched of Neostigmine Methylsulfate Injection, USP, a therapeutic ...
Janssen's Tremfya Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis
13 September 2018 - - The Janssen Pharmaceutical Companies of Johnson and Johnson (NYSEL JNJ) has released new data that show considerable improvements in long-term patient-reported outcomes in patien...